Recent studies identified dysregulated pathways in glioma, including PI3K/Akt/mTOR (cell survival), MAPK/ERK (cell growth), TP53 (cell cycle and DNA repair), RB pathway (cell cycle progression), IDH Mutation (metabolism and epigenetics), EGFR Amplification/Mutation (growth and therapy resistance), NF-κB pathway (inflammation and progression), and autophagy pathway (survival and therapy response) [3,4]. This evidence concerns the gene MTOR and central nervous system cancer.